These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 12748238)
1. A rational basis for selection among drugs of the same class. Brown MJ Heart; 2003 Jun; 89(6):687-94. PubMed ID: 12748238 [No Abstract] [Full Text] [Related]
2. Cardiovascular therapeutics. Shakur R; Cockrum E; Scott D Br J Hosp Med (Lond); 2008 Sep; 69(9):M136-40. PubMed ID: 18819300 [No Abstract] [Full Text] [Related]
4. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Choudhry NK; Brennan T; Toscano M; Spettell C; Glynn RJ; Rubino M; Schneeweiss S; Brookhart AM; Fernandes J; Mathew S; Christiansen B; Antman EM; Avorn J; Shrank WH Am Heart J; 2008 Jul; 156(1):31-6. PubMed ID: 18585494 [TBL] [Abstract][Full Text] [Related]
5. Long term medical treatment of stable coronary disease. Shavelle DM Heart; 2007 Nov; 93(11):1473-7. PubMed ID: 17934010 [No Abstract] [Full Text] [Related]
6. Letter regarding article by Rosenhek et al, "statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis". Routledge HC; Townend JN Circulation; 2005 May; 111(17):e274-5; author reply e274-5. PubMed ID: 15867188 [No Abstract] [Full Text] [Related]
7. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S; Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706 [TBL] [Abstract][Full Text] [Related]
8. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? Sigvant B; Henriksson M; Lundin F; Wahlberg E Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673 [TBL] [Abstract][Full Text] [Related]
9. Primary prevention of myocardial infarction: putting the evidence to use. Herzog E; Javed F Arch Intern Med; 2010 Aug; 170(15):1381-2. PubMed ID: 20696965 [No Abstract] [Full Text] [Related]
10. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Chłopicki S; Gryglewski RJ Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489 [TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?]. Gysling E Praxis (Bern 1994); 1995 Oct; 84(44):1248-51. PubMed ID: 7491446 [TBL] [Abstract][Full Text] [Related]
12. Drugs for chronic heart failure. Med Lett Drugs Ther; 2015 Jan; 57(1460):9-13. PubMed ID: 25581106 [No Abstract] [Full Text] [Related]